Key result
Rosuvastatin treatment increased paraoxonase 1 (PON1) activity by 19.1% at 8 weeks, improving anti-oxidative properties regardless of on-treatment HDL-C levels in patients with stable ischemic heart disease.
Why the study?
Does rosuvastatin 10 mg improve anti-oxidative properties in patients with stable ischemic heart disease and decreased HDL-C?
Cohort (n=240)
No
Does rosuvastatin 10 mg improve anti-oxidative properties in patients with stable ischemic heart disease and decreased HDL-C?
Rosuvastatin 10 mg improves anti-oxidative properties (PON1 activity) in patients with stable ischemic heart disease, independent of its effect on HDL-C levels.
Answers are grounded in this paper and cite their sources.
May enhance anti-oxidative capacity with rosuvastatin in stable IHD independent of HDL-C; leaves open effects on clinical outcomes.
BACKGROUND AND OBJECTIVES: The clinical significance of statin-induced high-density lipoprotein cholesterol (HDL-C) changes is not well known. We investigated whether rosuvastatin-induced HDL-C changes can influence the anti-oxidative action of high-density lipoprotein particle. SUBJECTS AND METHODS: A total of 240 patients with stable ischemic heart disease were studied. Anti-oxidative property was assessed by paraoxonase 1 (PON1) activity. We compared the lipid profile and PON1 activity at baseline and at 8 weeks after rosuvastatin 10 mg treatment. RESULTS: Rosuvastatin treatment increased the mean HDL-C concentration by 1.9±9.2 mg/dL (6.4±21.4%). HDL-C increased in 138 patients (57.5%), but decreased in 102 patients (42.5%) after statin treatment. PON1 activity increased to 19.1% in all patients. In both, the patients with increased HDL-C and with decreased HDL-C, PON1 activity significantly increased after rosuvastatin treatment (+19.3% in increased HDL-C responder; p=0.018, +18.8% in decreased HDL-C responder; p=0.045 by paired t-test). Baseline PON1 activity modestly correlated with HDL-C levels (r=0.248, p=0.009); however, the PON1 activity evaluated during the course of the treatment did not correlate with HDL-C levels (r=0.153, p=0.075). CONCLUSION: Rosuvastatin treatment improved the anti-oxidative properties as assessed by PON1 activity, regardless of on-treatment HDL-C levels, in patients with stable ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Park et al. (2016) conducted a cohort in Stable ischemic heart disease (n=240). Rosuvastatin vs. Baseline was evaluated on Change in paraoxonase 1 (PON1) activity. Rosuvastatin treatment increased paraoxonase 1 (PON1) activity by 19.1% at 8 weeks, improving anti-oxidative properties regardless of on-treatment HDL-C levels in patients with stable ischemic heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: